Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

5.1%

2 terminated/withdrawn out of 39 trials

Success Rate

94.1%

+7.6% vs industry average

Late-Stage Pipeline

10%

4 trials in Phase 3/4

Results Transparency

50%

16 of 32 completed trials have results

Key Signals

2 recruiting16 with results

Enrollment Performance

Analytics

Phase 2
18(47.4%)
Phase 1
16(42.1%)
Phase 3
4(10.5%)
38Total
Phase 2(18)
Phase 1(16)
Phase 3(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (39)

Showing 20 of 39 trials
NCT05586230Phase 1Recruiting

Study of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children With Rifampicin-Resistant Tuberculosis

Role: collaborator

NCT06481163Phase 2Recruiting

Telacebec (T) Treatment in Adults With Buruli Ulcer (BU).

Role: collaborator

NCT02333799Phase 3Completed

A Phase 3 Trial Assessing Safety and Efficacy of B-Pa-L in Participants With DR-TB

Role: lead

NCT05175794Completed

Triage Test for All Oral DR-TB Regimen (TRiAD Study)

Role: collaborator

NCT04865536Phase 1Completed

Study to Evaluate Safety, Tolerability, and the PK Profile of TBI-223 in Healthy Subjects

Role: lead

NCT04493671Phase 1Completed

Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults

Role: lead

NCT05686356Phase 2Active Not Recruiting

A Pan-TB Regimen Targeting Host and Microbe

Role: collaborator

NCT05971602Phase 2Terminated

Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis

Role: collaborator

NCT06058299Phase 2Active Not Recruiting

Phase 2 Trial Assessing TBAJ876 or Bedaquiline, with Pretomanid and Linezolid in Adults with Drug-sensitive Pulmonary Tuberculosis

Role: lead

NCT04179500Phase 2Completed

A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis

Role: lead

NCT03758612Phase 1Completed

A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults

Role: lead

NCT05526911Phase 1Completed

A Phase 1, Drug-Drug Interaction Study of TBAJ-876 in Healthy Adults

Role: lead

NCT04309656Phase 1Completed

Single-dose Study in Two Panels of Healthy Adult Participants to Assess Immediate-Release and Dispersible Formulations of Pretomanid

Role: lead

NCT02589782Phase 2Completed

Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)

Role: collaborator

NCT03338621Phase 2Completed

Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients

Role: lead

NCT03537495Phase 2Completed

Pharmacokinetic Study of Linezolid for TB Meningitis

Role: collaborator

NCT03086486Phase 3Completed

Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis

Role: lead

NCT04890535Phase 1Completed

Evaluation of the Safety, Tolerability, PK of TBAJ-587 in Healthy Adults

Role: lead

NCT04081077Phase 2Unknown

PRACTECAL-PKPD Sub Study

Role: collaborator

NCT00944021Phase 2Completed

Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (CL-010)

Role: lead